Table 1 Baseline characteristics of patients

Age (yrs)

61.6 ± 10.0

Woman (n,%)

15 (56)

Median disease duration (yrs, p25-p75)

11.2 (4.2- 17.4)

Median number of previous DMARDs (n)

2.5 (2.0- 3.3)

Previously treated with another biological (n, %)

3 (11%)

Rheumatoid factor positive (n,%)

21 (78)

Duration of infliximab therapy (yrs)

3.7 ± 2.3

Interval infliximab infusions (wks)

6.8 ± 2.0

Disease Activity at baseline

   Remission (n,%)

7 (26)

   Low disease activity (n,%)

6 (22)

   Moderate disease activity (n,%)

11 (41)

   High disease activity (n,%)

3 (11)

DMARD at baseline (n,%)

23 (85)

   Methotrexate (n,%)

17 (63)

   Dose (mg/week)

16.8 ± 5.5

   Azathioprine (n,%)

4 (15%)

Prednisone at baseline (n, %)

5 (19%)

   Dose (mg/day)

5.8 ± 1.8